Metacrine, a Rich Heyman biotech targeting NASH and other liver diseases, raises $85M from IPO

Max Gelman

Senior Editor

A Rich Heyman-backed startup focusing on NASH treatments, as well as other liver, GI and metabolic diseases, is set to start trading Wednesday and join …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Metacrine, a Rich Heyman biotech targeting NASH and other liver diseases, raises $85M from IPO

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Metacrine, a Rich Hey­man biotech tar­get­ing NASH and oth­er liv­er dis­eases, rais­es $85M from IPO

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Metacrine, a Rich Heyman biotech targeting NASH and other liver diseases, raises $85M from IPO